Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A -Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group.
Romy E Van WeelderenKim KleinChristine J HarrisonYilin JiangJonas AbrahamssonNira Arad-CohenEmmanuelle Bart-DelabesseBarbara BuldiniBarbara De MoerlooseMichael N DworzakSarah ElitzurJosé M Fernández NavarroRobert B GerbingBianca F GoemansHester A de Groot-KrusemanErin M GuestShau-Yin HaHenrik HasleCharikleia KelaidiHélène LapillonneGuy LevergerFranco LocatelliRiccardo MasettiTakako MiyamuraUlrika Norén-NyströmSophia PolychronopoulouMareike RascheJeffrey E RubnitzJan StaryAnne TierensDaisuke TomizawaChristian Michel ZwaanGertjan J L KaspersPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
-r AML. Treatment approaches other than allo-SCT in CR1 are needed to improve prognosis.